Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13405875 | 0.87 | GAA (0.67) | LMNAGAAKMT2ASMN1; SMN2HTT | |
| SCHEMBL22633565 | 0.84 | GAA (0.61) | LMNAGAAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL13406150 | 0.82 | SMN1; SMN2 (0.52) | LMNAGAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL22650873 | 0.82 | SMN1; SMN2 (0.77) | LMNAGAAKMT2ASMN1; SMN2HTT | |
| SCHEMBL22650871 | 0.79 | GAA (0.72) | LMNAGAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL23649505 | 0.76 | KCNA5 (0.60) | LMNAGAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL13405871 | 0.74 | MAPT (0.76) | LMNAGAASMN1; SMN2MAPTPKM | |
| SCHEMBL12768589 | 0.74 | GAA (0.77) | LMNAGAAKMT2ASMN1; SMN2PKM | |
| SCHEMBL13762620 | 0.73 | HDAC1 (0.65) | KMT2APOLB | |
| SCHEMBL2951701 | 0.73 | CYP19A1 (0.71) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1678145-A2 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050209282-A1 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-22 | — | — | US | disclosed |
| WO-2005042497-A2 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209282-A1 | Benzimidazoles useful as modulators of ion channels | KCNJ11, KCNJ1, KCNJ2 | LMNA 2494/4885GAA 1478/4885KMT2A 1737/4885 |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ11, KCNJ1, KCNJ2 | LMNA 2494/4885GAA 1478/4885KMT2A 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.